Nivolumab, a new hope in non-small cell lung cancer

被引：1

作者：

Flippot, Ronan ^{[1
]}

Fallet, Vincent ^{[2
]}

Besse, Benjamin ^{[1
]}

Massard, Christophe ^{[1
]}

Wislez, Marie ^{[2
]}

Vignot, Stephane ^{[3
]}

机构：

[1] Gustave Roussy Canc Campus, Dept Oncol Med, F-94800 Villejuif, France

[2] Hop Tenon, AP HP, Serv Pneumol, F-75020 Paris, France

[3] Hop Louis Pasteur, Serv Oncol & Hematol, F-28630 Chartres, France

来源：

BULLETIN DU CANCER | 2015年 / 102卷 / 12期

关键词：

Nivolumab; Immunotherapy; Non-small cell lung cancer; DOUBLE-BLIND; PHASE-I; ANTI-PD-1; MELANOMA; SAFETY; IPILIMUMAB; BMS-936558; ONO-4538; DOCETAXEL; BLOCKADE;

D O I：

10.1016/j.bulcan.2015.10.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancer accounts for 10% of cancer cases, but leads to 20% of cancer-specific mortality. Therapeutic options are limited, especially in tumors, which do not harbour druggable oncogenic alterations, and overall survival falls short of two years in the metastatic setting. The arrival of immunotherapy is a new hope for the achievement of an improved and sustainable survival in lung cancer patients. The approval of Nivolumab in this setting will lead to drastic changes in clinical practice. For optimal patient care, it will be essential to integrate the benefits and risks of such treatment. This review aims at discussing the role of nivolumab in lung cancer, in consideration of updated clinical data for safety and efficacy.

引用

页码：1046 / 1052

页数：7

共 50 条

[1] Nivolumab for treating non-small cell lung cancer
Guibert, Nicolas
Mazieres, Julien
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (12) : 1789 - 1797
[2] Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer
Morgensztern, Daniel
Herbst, Roy S.
[J]. CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3713 - 3717
[3] Perioperative Nivolumab in non-small cell Lung Cancer
Lorenz, Judith
[J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (18) : 1065 - 1066
[4] Amivantamab: A New Hope in Targeting Non-small Cell Lung Cancer
Billowria, Koushal
Das Gupta, Ghanshyam
Chawla, Pooja A.
[J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (02) : 124 - 141
[5] Non-small cell lung cancer: New hope for a chronic illness
Tyson, Leslie B.
[J]. ONCOLOGY NURSING FORUM, 2007, 34 (05) : 963 - 970
[6] Nivolumab in a patient with HIV and non-small cell lung cancer
Hentrich, M.
Schipek-Voigt, K.
Jaeger, H.
Schulz, S.
Schmid, P.
Stoetzer, O.
Bojko, P.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 232 - 232
[7] Nivolumab plus chemotherapy for non-small cell lung cancer
Lichert, Frank
[J]. PNEUMOLOGIE, 2024, 78 (02): : 81 - 81
[8] Combination of nivolumab with radiotherapy for non-small cell lung cancer
Cihan, Y. B.
[J]. ARCHIVES OF HELLENIC MEDICINE, 2022, 39 (06): : 857 - 858
[9] Nivolumab in non-small cell lung cancer: is there an upper age limit?
De Pietro, L.
Vitiello, F.
Gilli, M.
Letizia, A.
Tortoriello, A.
Hengeller, M.
Mazzarella, G.
Bianco, A.
Piantedosi, F.
[J]. ANNALS OF ONCOLOGY, 2017, 28
[10] Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer
Keating, Gillian M.
[J]. DRUGS, 2016, 76 (09) : 969 - 978

← 1 2 3 4 5 →